A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
The main aim is to check the long-term side effects of treatment with Brentuximab Vedotin and
to see if that treatment improves symptoms of cluster of differentiation antigen 30
(CD30-Positive) Cutaneous T-Cell Lymphoma in Chinese adults.
Participants will receive brentuximab vedotin through the vein on day 1 of each 21 day cycle
up to maximum 16 cycles.